News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cobra BioManufacturing (CBF.L) Announces Manufacturing Agreement With Pharmexa


2/2/2007 1:43:20 PM

Keele, UK, 1 February 2007: UK-based Cobra Biomanufacturing Plc (AIM: CBF) today announces an agreement with Pharmexa for the manufacture of the protein vaccine PX107 for use in Phase I clinical trials for bone disorders. The program will include cell banking, process development and GMP manufacture.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES